In vitro investigation of osteogenic differentiation and bone regeneration potential of magnesium oxide nanoparticles incorporated into bacterial cellulose/silk fibroin scaffolds.
Niknafs B., Ahangar P., Meskaraf-Asadabadi M., Ghanbari E.
Laboratory Study, published in Sci Rep (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Sci Rep (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42036436
- PMCID
- PMC13284262
- DOI
- 10.1038/s41598-026-50227-5
Abstract (original English)
This study developed porous scaffolds composed of silk fibroin (SF), bacterial cellulose (BC), and magnesium oxide nanoparticles (MgONPs) via freeze-drying to investigate their potential for bone tissue engineering (BTE). The scaffolds were characterized using scanning electron microscopy (SEM) and Fourier transform infrared spectroscopy (FTIR), and assessed for porosity, compressive strength, swelling ratio, and degradation rate. Biological evaluations included cell attachment, proliferation, and osteogenic differentiation of human adipose-derived stem cells (hASCs). Results indicated that the incorporation of MgONPs influenced scaffold properties, leading to a decrease in pore size and swelling capacity (p = 0.001). MTT assay confirmed high cell viability across all scaffolds, with BC/SF/MgONPs demonstrating enhanced biocompatibility after 72 h (p = 0.016 vs. SF). Furthermore, BC/SF and BC/SF/MgONPs scaffolds exhibited minimal hemolysis, suggesting improved hemocompatibility. Alkaline phosphatase (ALP) activity and alizarin red S staining analyses revealed significantly increased osteogenic potential for BC/SF/MgONPs scaffolds compared to SF scaffolds (p = 0.027 and p = 0.002, respectively vs. SF). Consistent with these findings, BC/SF/MgONPs scaffolds led to a significant increase in the expression of early and late osteogenic markers, namely RUNX2 (p = 0.001), ALP (p = 0.00
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.